Albendazole

DRUG INFORMATION

  ADULT
    - DOSAGE & ADMINISTRATION Patients weighing 60 kg or greater, 400 mg twice daily;
      less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily
      dose 800 mg).
      Source: US FDA label for albendazole (Albendazole), section 'dosage and
      administration', retrieved 2026-08-29
    - DOSAGE & ADMINISTRATION Patients weighing 60 kg or greater, 400 mg twice daily;
      less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily
      dose 800 mg). Albendazole Tablets should be taken with food. ( 2 ) Hydatid
      disease: 28‑day cycle followed by 14‑day albendazole‑free interval for a total of
      3 cycles. ( 2 ) Neurocysticercosis: 8 to 30 days. ( 2 ) See additional important
      information in the Full Prescribing Information.
      Source: US FDA label for albendazole (Albendazole), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Hydatid disease is uncommon in infants and young children. In neurocysticercosis,
      the efficacy of Albendazole Tablets in children appears to be similar to that in
      adults.
      Source: US FDA label for albendazole (Albendazole), section 'pediatric use',
      retrieved 2026-08-29
    - DOSAGE & ADMINISTRATION Patients weighing 60 kg or greater, 400 mg twice daily;
      less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily
      dose 800 mg). Albendazole Tablets should be taken with food. ( 2 ) Hydatid
      disease: 28‑day cycle followed by 14‑day albendazole‑free interval for a total of
      3 cycles. ( 2 ) Neurocysticercosis: 8 to 30 days. ( 2 ) See additional important
      information in the Full Prescribing Information.
      Source: US FDA label for albendazole (Albendazole), section 'dosage and
      administration', retrieved 2026-08-29
    - DOSAGE & ADMINISTRATION Patients weighing 60 kg or greater, 400 mg twice daily;
      less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily
      dose 800 mg).
      Source: US FDA label for albendazole (Albendazole), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for albendazole (Albendazole),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Patients with liver disease and patients with hepatic echinococcosis are at
      increased risk for bone marrow suppression and warrant more frequent monitoring of
      blood counts.
      Source: US FDA label for albendazole (Albendazole), section 'warnings and
      cautions', retrieved 2026-08-29
    - There have also been case reports of acute liver failure of uncertain causality
      and hepatitis [ see Adverse Reactions ( 6 ) ].
      Source: US FDA label for albendazole (Albendazole), section 'warnings and
      cautions', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Based on findings from animal reproduction studies, Albendazole
      Tablets may cause fetal harm when administered to a pregnant woman.
      Source: US FDA label for albendazole (Albendazole), section 'pregnancy', retrieved
      2026-08-29
    - However, available human data from a small number of published case series and
      reports on the use of multiple-dose albendazole in the 1 st trimester of
      pregnancy, and several published studies on single-dose albendazole use later in
      pregnancy, have not identified any drug-associated risks for major birth defects,
      miscarriage, or adverse maternal or fetal outcomes.
      Source: US FDA label for albendazole (Albendazole), section 'pregnancy', retrieved
      2026-08-29
    - In animal reproductive studies, oral administration of albendazole during the
      period of organogenesis caused embryotoxicity and skeletal malformations in
      pregnant rats (at doses of 0.10 times and 0.32 times the maximum recommended human
      dose based on body surface area in mg/m 2 ) and pregnant rabbits (at doses of 0.60
      times the maximum recommended human dose based on body surface area in mg/m 2 ).
      Source: US FDA label for albendazole (Albendazole), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Pregnancy Testing Pregnancy testing is recommended for females of reproductive
      potential prior to initiating Albendazole Tablets.
      Source: US FDA label for albendazole (Albendazole), section 'nursing mothers',
      retrieved 2026-08-29
    - Contraception Females Albendazole Tablets may cause fetal harm when administered
      to a pregnant woman [see Use in Specific Populations ( 8.1 )].
      Source: US FDA label for albendazole (Albendazole), section 'nursing mothers',
      retrieved 2026-08-29
    - Advise females of reproductive potential to use effective contraception during
      treatment with Albendazole Tablets and for 3 days after the final dose.
      Source: US FDA label for albendazole (Albendazole), section 'nursing mothers',
      retrieved 2026-08-29